NEW YORK--(BUSINESS WIRE)--
Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NASDAQ:ALXN) concerning possible violations of federal securities laws by certain officers and directors.
On November 9, 2016, Alexion announced that is investigating accusations of improper sales practices involving its top drug, Soliris. The Company has retained outside counsel and announced its decision to delay its third-quarter financial report. When this news was revealed, shares of Alexion fell in value. To obtain additional information about the investigation, go to:
http://zlk.9nl.com/alexion-pharmaceuticals-alxn
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30
Broad Street - 24th Floor
New York, NY 10004
Tel: (212)
363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005893/en/
